A STUDY ON ADHERENCE PATTERNS , TOXICITIES AND QUALITY OF LIFE OF PATIENTS WITH PROGRESSIVE ADULT MALIGNANCIES ON METRONOMIC CHEMOTHERAPY

Objective: This study was conducted to assess the medication adherence patterns, toxicities and the quality of life of the patients with progressive solid malignancies, receiving metronomic chemotherapy. Materials and Methods: 51 patients of either sex, aged above 18 years, attending the medical oncology unit of a tertiary care teaching hospital were included and data on demographics and cancer chemotherapy was obtained. The overall adherence towards chemotherapy was assessed by 8 itemed Morisky adherence scale, patients’ propensity towards adherence was determined by Merck`s Adherence Estimator, quality of life of patients was assessed by European Organization for Research and Treatment of Cancer QLQ-30 and toxicities through Common Toxicity Criteria rating scale. Results: The study identified haematological side effects (25.4%) like neutropenia, anemia and thrombocytopenia as grade-3 and grade-4 toxicities. All other toxicities were of grade-1 and grade-2 type. According to morisky adherence scale 88.2% patients showed medium adherence. By Merck’s adherence estimator 55% had a high risk for nonadherence due to sentimental reasons and financial burden of the chemotherapy. Conclusion: Metronomic chemotherapy had less severe ADRs and the requirement for the administration of intravenous drugs was minimized which benefits the patients who are often too sick to travel frequently to the hospitals.

[1]  O. Tsitsilonis,et al.  The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients , 2014, Experimental Hematology & Oncology.

[2]  K. Mross,et al.  Metronomic anti-cancer therapy - an ongoing treatment option for advanced cancer patients , 2012 .

[3]  D. Generali,et al.  Use of metronomic chemotherapy in oncology: results from a national Italian survey. , 2011, Tumori.

[4]  N. André,et al.  Children Treated With Metronomic Chemotherapy in a Low-income Country: METRO-MALI-01 , 2011, Journal of pediatric hematology/oncology.

[5]  Nicolas André,et al.  Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.

[6]  U. Dafni,et al.  Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer , 2009, Clinical Cancer Research.

[7]  N. André,et al.  Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. , 2008, Clinical therapeutics.

[8]  N. André,et al.  Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. , 2007, Current cancer drug targets.

[9]  C. Tiu,et al.  Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer , 2007, Cancer Chemotherapy and Pharmacology.

[10]  P. Cano,et al.  Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors , 2006, Clinical Cancer Research.

[11]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[12]  C. Unger,et al.  Palliative Chemotherapy in Pretreated Patients with Advanced Cancer: Oral Trofosfamide Is Effective in Ovarian Carcinoma , 2001, Cancer investigation.

[13]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[14]  A. Nacci,et al.  Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. , 2012, European journal of cancer.